Chronic Cough Market Report 2026

The chronic cough market size has grown strongly in recent years. It will grow from $8.87 billion in 2025 to $9.71 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to rising prevalence of asthma and allergies, increased awareness of chronic respiratory conditions, wider availability of over-the-counter cough medications, improved diagnostic capabilities for respiratory disorders, expansion of outpatient respiratory care.

The chronic cough market size is expected to see strong growth in the next few years. It will grow to $14.17 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing focus on personalized respiratory treatments, rising investments in novel cough therapeutics, growing demand for non-opioid cough suppressants, expansion of telehealth-based respiratory care, increasing emphasis on long-term symptom management. Major trends in the forecast period include increasing development of targeted antitussive therapies, rising focus on combination drug formulations, growing adoption of long-acting cough suppressants, expansion of acid reflux-linked cough treatments, enhanced emphasis on differential diagnosis approaches.

The rising prevalence of smoking and tobacco use is expected to drive growth in the chronic cough market. Smoking, the act of burning substances such as tobacco and inhaling the resulting smoke, irritates the airways, contributes to chronic bronchitis, increases mucus production, reduces lung function, weakens the immune system, interferes with the cough reflex, and elevates the risk of lung cancer. For example, in October 2024, according to the UK’s Office for National Statistics (ONS), approximately 6 million adults in the UK - representing 11.9% of the population aged 18 and over - were cigarette smokers in 2023. Therefore, the increasing prevalence of smoking and tobacco use is fueling the growth of the chronic cough market.

Major companies in the chronic cough market are focusing on innovative product development, including biosimilars, to strengthen their market presence. Biosimilars provide cost-effective alternatives to existing biologics for treating conditions such as cancer, autoimmune disorders, and diabetes. For instance, in July 2024, Sandoz, a Switzerland-based pharmaceutical company, launched its biosimilar Pyzchiva (ustekinumab) across Europe, targeting chronic inflammatory diseases including plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Pyzchiva is notable as the first biosimilar in Europe available in all reference medicine strengths, including the initiation dose for Crohn’s disease. Developed in partnership with Samsung Bioepis, the launch reflects Sandoz’s commitment to improving patient access to effective therapies and enhancing quality of life across Europe.

In June 2023, GSK Plc., a UK-based global healthcare company, acquired BELLUS Health, a Canada-based clinical-stage biopharmaceutical company specializing in chronic cough treatments, for an undisclosed amount. Through this acquisition, GSK aims to strengthen its rare disease portfolio, accelerate the development and commercialization of innovative therapies, and expand its presence in the global specialty pharmaceutical market.

Major companies operating in the chronic cough market are Tris Pharma Inc., Pfizer Inc., Johnson & Johnson Co, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Glaxo SmithKline Plc, Merck KGaA, Reckitt Benckiser Group plc, Glenmark Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma Ltd., Cipla Limited, Apotex Inc., Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals LLC, Mount Sinai Health System, Biocon Ltd., BELLUS Health Inc., Trevi Therapeutics Inc., Sun Pharmaceutical Industries Ltd., NeRRe Therapeutics Ltd.

North America was the largest region in the chronic cough market in 2025. The regions covered in the chronic cough market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic cough market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic cough market by increasing costs of imported active pharmaceutical ingredients, excipients, inhalation devices, and packaging materials used in antihistamines, corticosteroids, and combination drug formulations. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on globally sourced raw materials, while Asia-Pacific faces pricing pressure on export-oriented drug production. These tariffs are contributing to higher manufacturing costs and pricing pressures across hospital and retail pharmacies. However, they are also encouraging domestic API production, localized formulation development, and greater supply chain diversification to ensure treatment availability.

The chronic cough market research report is one of a series of new reports that provides chronic cough market statistics, including chronic cough industry global market size, regional shares, competitors with a chronic cough market share, detailed chronic cough market segments, market trends and opportunities, and any further data you may need to thrive in the chronic cough industry. This chronic cough market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic cough is a persistent cough that lasts for an extended period, typically eight weeks or longer. It often serves as a symptom of an underlying condition, such as asthma, allergies, or respiratory infections.

The main drug classes for chronic cough include antihistamines, corticosteroids, decongestants, combination drugs, antibiotics, acid blockers, and others. Antihistamines are medications designed to treat allergic reactions caused by the physiological effects of histamines. The routes of administration include oral, inhalational, injectable, and others. These drugs are used across hospitals, homecare settings, specialty centers, and other healthcare facilities, with distribution through hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic cough market consists of revenues earned by entities by providing services such as chest X-ray or CT scan services, lung function tests, and sputum culture. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic cough market also includes sales of cough suppressants, expectorants, inhalers, and allergy medications which are used in providing the services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.